Molecular diagnostic firm Biocept announced Monday that it has signed two new agreements with preferred provider organization networks — Fortified Provider Network and Three Rivers Provider Network.
The deals mean about 26 million members of these two PPOs will now have covered access to Biocept’s target selector non-invasive liquid biopsy assays, which include tests for melanoma, breast, lung, and gastric cancer biomarkers.
Fortified Provider Network is a PPO used by self-funded employer groups, insurance carriers, and local provider networks. Three Rivers is one of the largest and fastest growing PPO networks in the nation with 550,000 providers and 5,000 hospitals, according to a news release from Biocept.
San Diego-based Biocept signed similar deals with three other PPOs — MultiPlan, Stratose, and Galaxy Health Network ― earlier this year.
According to the press release, its new deals with FPN and Three Rivers bring the total number of consumers with health plan access to its liquid biopsy testing to about 133 million.